Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Scientists image structure of bacterium protein coat

Scientists image structure of bacterium protein coat

'Killer silk' can kill anthrax in minutes

'Killer silk' can kill anthrax in minutes

Special feature of Science journal highlights protein array technology

Special feature of Science journal highlights protein array technology

First Edition: May 18, 2012

First Edition: May 18, 2012

FDA approves Emergent’s BioThrax sBLA to treat anthrax disease

FDA approves Emergent’s BioThrax sBLA to treat anthrax disease

Soligenix first quarter revenues decrease to $647,418

Soligenix first quarter revenues decrease to $647,418

Aradigm first quarter total revenue increases to $0.3 million

Aradigm first quarter total revenue increases to $0.3 million

iBio receives U.S. patent for iBioModulator platform

iBio receives U.S. patent for iBioModulator platform

State roundup: Calif. fight over group homes for seniors; New agency proposed to police disabled care in NY; Conn. retiree health plan expansion could endanger protections

State roundup: Calif. fight over group homes for seniors; New agency proposed to police disabled care in NY; Conn. retiree health plan expansion could endanger protections

Highlights: D.C. may have funds for illegal immigrant health care; Fla. passed up $200M because it comes from health law; Texas to build 2 new med schools

Highlights: D.C. may have funds for illegal immigrant health care; Fla. passed up $200M because it comes from health law; Texas to build 2 new med schools

Soldiers, farmers can have common chronic exposure to nerve impacting chemicals

Soldiers, farmers can have common chronic exposure to nerve impacting chemicals

PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine

PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Farzad Mostashari: Focusing on moving doctors into the digital age

Farzad Mostashari: Focusing on moving doctors into the digital age

Emergent BioSolutions fourth quarter total revenues increase to $107.9M

Emergent BioSolutions fourth quarter total revenues increase to $107.9M

PharmAthene revenue increases to $24.3M for year ended December 31, 2011

PharmAthene revenue increases to $24.3M for year ended December 31, 2011

Scientists determine chemical features of DHPS enzyme's active site

Scientists determine chemical features of DHPS enzyme's active site

Sandia's decontamination foam now used for meth lab cleanup

Sandia's decontamination foam now used for meth lab cleanup

Preliminary results from Soligenix SGX201 Phase 1/2 trial on acute radiation enteritis

Preliminary results from Soligenix SGX201 Phase 1/2 trial on acute radiation enteritis

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology